NCT02139592View on ClinicalTrials.gov

"Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

CompletedOBSERVATIONAL
Enrollment

292

Participants

Timeline

Start Date

April 17, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Interventions
DRUG

Brentuximab vedotin (recombinant)

Brentuximab vedotin (recombinant) for IV infusion

Trial Locations (1)

Unknown

Osaka

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02139592 - "Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" | Biotech Hunter | Biotech Hunter